Shares of BioDelivery Sciences Intl BDSI rose 6.1% in pre-market trading after the company reported Q4 results.
Quarterly Results
Earnings per share rose 66.67% year over year to $0.10, which beat the estimate of $0.06.
Revenue of $42,167,000 rose by 33.28% from the same period last year, which beat the estimate of $38,720,000.
Guidance
The upcoming fiscal year's revenue expected to be between $170,000,000 and $180,000,000.
Conference Call Details
Date: Mar 10, 2021
Time: 08:30 AM
ET Webcast URL: https://viavid.webcasts.com/starthere.jsp?ei=1424252&tp_key=cc62779967
Technicals
Company's 52-week high was at $5.45
52-week low: $2.85
Price action over last quarter: Up 29.46%
Company Profile
BioDelivery Sciences International Inc is a rapidly growing commercial-stage specialty pharmaceutical company dedicated to patients living with chronic pain. The company is utilizing its novel and proprietary BioErodible MucoAdhesive (BEMA) technology and other drug delivery technologies to develop and commercialize, either on its own or in partnership with third parties, new applications of therapies aimed at addressing important unmet medical needs. Its marketed products and those in development address serious and debilitating conditions such as chronic pain, breakthrough cancer pain, and opioid dependence.
© 2024 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.
Comments
Trade confidently with insights and alerts from analyst ratings, free reports and breaking news that affects the stocks you care about.